We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+37.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.2B
AUM Growth
+$120M
Cap. Flow
-$379M
Cap. Flow %
-17.19%
Top 10 Hldgs %
84.63%
Holding
41
New
11
Increased
2
Reduced
3
Closed
11
Avg Time Held Equity + Options
7.6 quarters
Top 10 Avg Time Held Equity + Options
4.4 quarters
Top 20 Avg Time Held Equity + Options
5.7 quarters
Avg Time Held Equity only
8.1 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
5.7 quarters

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$65M
2
CGON icon
CG Oncology
CGON
+$31.9M
3
ZBIO icon
Zenas BioPharma
ZBIO
+$26M
4
PCVX icon
Vaxcyte
PCVX
+$20.1M
5
MREO icon
Mereo BioPharma
MREO
+$15M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$233M
2
TNGX icon
Tango Therapeutics
TNGX
+$89.3M
3
APLS icon
Apellis Pharmaceuticals
APLS
+$78M
4
XNCR icon
Xencor
XNCR
+$43.2M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Miscellaneous 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZYME icon
1
Zymeworks
ZYME
$1.8B
$605M 27.44%
22,970,388
– –
2022 Q4
12 quarters
ANAB icon
2
AnaptysBio
ANAB
$1.36B
$382M 17.33%
7,880,094
– –
2019 Q4
24 quarters
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$13.7B
$290M 13.16%
1,706,469
– –
2023 Q2
10 quarters
CRNX icon
4
DELISTED
Crinetics Pharmaceuticals
CRNX
$200M 9.06%
4,288,120
– –
2021 Q4
16 quarters
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$77.9M 3.53%
3,115,000
+2,565,000
+466% +$65M
2025 Q3
1 quarter
CRSP icon
6
CRISPR Therapeutics
CRSP
$4.84B
$72.9M 3.31%
1,389,276
– –
2024 Q1
7 quarters
MBX icon
7
MBX Biosciences
MBX
$2.36B
$67M 3.04%
2,123,604
– –
2024 Q3
5 quarters
IMNM icon
8
Immunome
IMNM
$2.07B
$61.3M 2.78%
2,855,590
-1,223,825
-30% -$21.5M
2023 Q4
8 quarters
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.17B
$55M 2.5%
6,728,116
– –
2020 Q2
22 quarters
LKFT icon
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$54.5M 2.47%
1,667,119
– –
2021 Q3
17 quarters
XNCR icon
11
Xencor
XNCR
$1.75B
$49.8M 2.26%
3,251,112
-2,893,655
-47% -$43.2M
2018 Q4
28 quarters
BBOT icon
12
BridgeBio Oncology
BBOT
$237M
$35.3M 1.6%
2,823,126
– –
2025 Q3
1 quarter
ETON icon
13
Eton Pharmaceutcials
ETON
$1.52B
$34.3M 1.56%
2,030,544
– –
2024 Q3
5 quarters
CGON icon
14
CG Oncology
CGON
$5.53B
$32.1M 1.45%
+772,000
New +$31.9M
2025 Q4
0 quarters
ZBIO icon
15
Zenas BioPharma
ZBIO
$1.64B
$28.7M 1.3%
+789,500
New +$26M
2025 Q4
0 quarters
NGNE icon
16
Neurogene
NGNE
$431M
$26.2M 1.19%
1,271,342
– –
2023 Q4
8 quarters
GPCR icon
17
Structure Therapeutics
GPCR
$1.59B
$23.3M 1.06%
+334,380
New +$13.7M
2025 Q4
0 quarters
PCVX icon
18
Vaxcyte
PCVX
$10.4B
$20.8M 0.94%
+450,000
New +$20.1M
2025 Q4
0 quarters
AQST icon
19
Aquestive Therapeutics
AQST
$586M
$17M 0.77%
2,625,000
– –
2025 Q3
1 quarter
VYGR icon
20
Voyager Therapeutics
VYGR
$132M
$15.7M 0.71%
4,002,847
+3,332,544
+497% +$14.7M
2021 Q3
17 quarters
CGON icon
21
CALL
CG Oncology
CGON
$5.53B
$12.2M 0.55%
+292,800
New +$12.1M
2025 Q4
0 quarters
ATRA icon
22
Atara Biotherapeutics
ATRA
$93.4M
$10.4M 0.47%
573,183
– –
2023 Q4
8 quarters
MNKD icon
23
MannKind Corp
MNKD
$981M
$9.41M 0.43%
+1,660,000
New +$9.14M
2025 Q4
0 quarters
NUVB.WS icon
24
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.63M 0.39%
963,333
– –
2021 Q1
19 quarters
EOLS icon
25
Evolus
EOLS
$496M
$4.49M 0.2%
+675,000
New +$4.57M
2025 Q4
0 quarters
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2025 Portfolio in Review

As of Q4 2025, EcoR1 Capital held 41 positions worth $2.2B, up 5.8% from $2.08B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

EcoR1 Capital withdrew a net $379M in Q4 2025, closing 11 positions and reducing 3 holdings. Its most notable exit was uniQure, an estimated $233M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in CG Oncology worth $32.1M.

  • EcoR1 Capital's largest Q4 2025 buy was CG Oncology: 772,000 shares worth $32.1M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q4 2025, an estimated $65M increase.
  • EcoR1 Capital's biggest Q4 2025 reduction was Xencor, cutting an estimated $43.2M.
  • EcoR1 Capital fully exited uniQure in Q4 2025, selling an estimated $233M.
  • EcoR1 Capital's ten largest holdings make up 85% of its $2.2B portfolio in Q4 2025.
  • EcoR1 Capital opened 11 new positions and closed 11 in Q4 2025.
  • EcoR1 Capital's portfolio value rose 5.8% quarter-over-quarter to $2.2B.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.